SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: jaybe who wrote (4223)4/27/2016 10:02:26 PM
From: medichem  Read Replies (1) of 4474
 
788 is very similar to AZD9291, I went through the patent, it is clear that 788 is a 3rd generation irreversible EGFR kinase inhibitor with subtle change of AZD9291's structure. That is where the activity to mutation comes from. Ariad has this platform to identify mutation quickly and based on that they can identify newer generation of kinase inhibitor faster. Do they get that from AZD9291? maybe, coz the structure is so close......IMHO
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News